SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-19-016235
Filing Date
2019-08-09
Accepted
2019-08-09 16:06:29
Documents
68
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20190630_10q.htm 10-Q 1075593
2 EXHIBIT 31.1 ex_152861.htm EX-31.1 9502
3 EXHIBIT 32.1 ex_152862.htm EX-32.1 4878
  Complete submission text file 0001437749-19-016235.txt   6527891

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT navb-20190630.xml EX-101.INS 1514724
5 XBRL TAXONOMY EXTENSION SCHEMA navb-20190630.xsd EX-101.SCH 53842
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20190630_cal.xml EX-101.CAL 40084
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20190630_def.xml EX-101.DEF 478238
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20190630_lab.xml EX-101.LAB 362127
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20190630_pre.xml EX-101.PRE 495540
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 191013009
SIC: 2835 In Vitro & In Vivo Diagnostic Substances